title: The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
abstract: BACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine.
  
  
  METHODS
  Colorectal cancer patients scheduled for capecitabine chemotherapy as adjuvant setting were randomly assigned to with or without concurrent oral pyridoxine (60 mg/d) groups. Patients were monitored whether being a development of National Cancer Institute Common Toxicity Criteria grade 2 or worse HFS until chemotherapy ended.
  
  
  RESULTS
  Sixty patients were enrolled in this study. Relative dose intensity was 89.5% in total. The median number of chemotherapy cycles to grade 2 or worse HFS was four in both groups. Grade 2 or worse HES developed in 18 (60.0%) of 30 control patients and in 18 (60.0%) of 30 pyridoxine patients. The cumulative dose of capecitabine to grade 2 or worse HFS was not different between the two groups.
  
  
  CONCLUSIONS
  Pyridoxine is not effective in prevention of capecitabine-associated HFS.
authors.forename: Mitsuyoshi
authors.initials: M
authors.lastname: Ota
authors.forename: Kenji
authors.initials: K
authors.lastname: Tatsumi
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Suwa
authors.forename: Jun
authors.initials: J
authors.lastname: Watanabe
authors.forename: Kazuteru
authors.initials: K
authors.lastname: Watanabe
authors.forename: Shunichi
authors.initials: S
authors.lastname: Osada
authors.forename: Kuniya
authors.initials: K
authors.lastname: Tanaka
authors.forename: Fujii
authors.initials: F
authors.lastname: Shoichi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Ichikawa
authors.forename: Chikara
authors.initials: C
authors.lastname: Kunisaki
authors.forename: Itaru
authors.initials: I
authors.lastname: Endo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives*; D060831:Hand-Foot Syndrome / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D011736:Pyridoxine / Q000627:therapeutic use*; D012307:Risk Factors; D013997:Time Factors; D017211:Treatment Failure; D055815:Young Adult
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D011736:Pyridoxine; D005472:Fluorouracil